Trifluridine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 12: | Line 12: | ||
''' [[Trifluridine description|Description]]''' | ''' [[Trifluridine description|Description]]''' | ||
'''| [[Trifluridine clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Trifluridine clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Trifluridine indications and usage|Indications and Usage]]''' | '''| [[Trifluridine indications and usage|Indications and Usage]]''' | ||
'''| [[Trifluridine contraindications|Contraindications]]''' | '''| [[Trifluridine contraindications|Contraindications]]''' | ||
| Line 20: | Line 19: | ||
'''| [[Trifluridine clinical studies|Clinical Studies]]''' | '''| [[Trifluridine clinical studies|Clinical Studies]]''' | ||
'''| [[Trifluridine dosage and administration|Dosage and Administration]]''' | '''| [[Trifluridine dosage and administration|Dosage and Administration]]''' | ||
'''| [[Trifluridine how supplied|How Supplied]]''' | '''| [[Trifluridine how supplied|How Supplied]]''' | ||
'''| [[Trifluridine labels and packages|Labels and Packages]]''' | '''| [[Trifluridine labels and packages|Labels and Packages]]''' | ||
Revision as of 15:40, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Category
Antiviral
US Brand Names
VIROPTIC®
FDA Package Insert
Description | Clinical Pharmacology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages